surtavi
play

SURTAVI Nicolas Dumonteil Toulouse Dclaration de Relations - PowerPoint PPT Presentation

Sep 22, 2023 •415 likes •737 views

Ce qui pourrait changer mes pratiques ou pas ! SURTAVI Nicolas Dumonteil Toulouse Dclaration de Relations Professionnelles Disclosure Statement of Financial Interest J'ai actuellement, ou j'ai eu au cours des deux dernires annes,

  1. Ce qui pourrait changer mes pratiques … ou pas ! SURTAVI Nicolas Dumonteil Toulouse

  2. Déclaration de Relations Professionnelles Disclosure Statement of Financial Interest J'ai actuellement, ou j'ai eu au cours des deux dernières années, une affiliation ou des intérêts financiers ou intérêts de tout ordre avec une société commerciale ou je reçois une rémunération ou des redevances ou des octrois de recherche d'une société commerciale : I currently have, or have had over the last two years, an affiliation or financial interests or interests of any order with a company or I receive compensation or fees or research grants with a commercial company : Company Affiliation/Financial Relationship • Consulting Fees / Honoraria • Medtronic • Edwards LifeScience • Boston Scientific • Abbott Vascular

  4. the SURTAVI trial Objective: to assess the safety and efficacy of TAVR with the self-expanding valve vs. surgical AVR in patients with symptomatic, severe aortic stenosis at intermediate surgical risk

  5. the SURTAVI trial Hypothesis: to show non inferiority of TAVR vs. SAVR for all-cause mortality or disabling stroke at 24 months in patients undergoing attempted AVR

  6. the SURTAVI trial Methods : - Multinational RCT (87 centers across USA, Canada and EU) - Patients with symptomatic severe AS, determined to be at intermediate risk by the local multidisciplinary heart team

  7. the SURTAVI trial Methods : Heart Team Predicted risk of Operative Mortality ≥ 3 % and < 15 % At 30 days

  8. the SURTAVI trial Methods (detailed): - Disabling stroke : VARC-2 defined (all patients seen by neurologist) - Clinical-events committee with independent neurologist - Independent echo core laboratory (Mayo Clinic) - Randomization stratified according to the need for coronary revascularization - TAVR sizing and access choice based on CT - TF access 1 st option for TAVR, sub clavian or direct aortic as alternatives

  9. the SURTAVI trial Methods (detailed): - Disabling stroke : VARC-2 defined (all patients seen by neurologist) - Clinical-events committee with independent neurologist - Independent echo core laboratory (Mayo Clinic) - Randomization stratified according to the need for coronary revascularization - TAVR sizing and access choice based on CT - TF access 1 st option for TAVR, sub clavian or direct aortic as alternatives

  10. the SURTAVI trial Methods (detailed): - Disabling stroke : VARC-2 defined (all patients seen by neurologist) - Clinical-events committee with independent neurologist - Independent echo core laboratory (Mayo Clinic) - Randomization stratified according to the need for coronary revascularization - TAVR sizing and access choice based on CT - TF access 1 st option for TAVR, sub clavian or direct aortic as alternatives

  11. the SURTAVI trial Methods (detailed): - Disabling stroke : VARC-2 defined (all patients seen by neurologist) - Clinical-events committee with independent neurologist - Independent echo core laboratory (Mayo Clinic) - Randomization stratified according to the need for coronary revascularization - TAVR sizing and access choice based on CT - TF access 1 st option for TAVR, sub clavian or direct aortic as alternatives

  12. the SURTAVI trial Methods (detailed): - Disabling stroke : VARC-2 defined (all patients seen by neurologist) - Clinical-events committee with independent neurologist - Independent echo core laboratory (Mayo Clinic) - Randomization stratified according to the need for coronary revascularization - TAVR sizing and access choice based on CT - TF access 1 st option for TAVR, sub clavian or direct aortic as alternatives

  13. the SURTAVI trial Trial Design Intermediate Surgical Risk Predicted risk of operative mortality ≥3% and <15% Heart Team Evaluation Screening Committee Assess inclusion/exclusion Risk classification Confirmed eligibility Randomization Baseline neurological Stratified by need for revascularization assessments TAVR SAVR TAVR only TAVR + PCI SAVR only SAVR + CABG

  14. the SURTAVI trial Statistical methods : - Randomization 1:1 to TAVR (Self-expanding valve) vs SAVR (bioprosthesis) - Bayesian statistical methodology * sample size of 1 600 attempted procedures assuming a 17 % incidence of the primary endpoint in surgery group * non inferiority margin of 0.07 - Modified intention-to-treat analysis : randomization and an attempted procedure

  16. MODIFIED INTENTION-TO-TREAT POPULATION

  18. Primary Endpoint : all-cause mortality or disabling stroke

  23. the SURTAVI trial CONCLUSION SURTAVI trial met its primary endpoint demonstrating that TAVR with a self-expanding CoreValve or Evolut R bioprosthesis is non inferior to SAVR for all-cause mortality or disabling stroke at 24 months in patients with symptomatic AS at intermediate risk for surgery

  24. the SURTAVI trial CONCLUSION • TAVR had significantly less 30 day stroke, AKI, atrial fibrillation and transfusion use and a superior quality of life at 30 days. • TAVR resulted in significantly improved AV hemodynamics with lower mean gradients and larger aortic valve areas than SAVR through 24 months. • SAVR had less residual aortic regurgitation, major vascular complications and fewer new pacemakers. • Need for a new pacemaker after TAVR was not associated with increased mortality.

  25. the SURTAVI trial General considerations CONCLUSION

  26. Back-up

  27. Bayesian Analysis of the 24-Month Primary Endpoint Analysis • A pre-specified interim analysis Trigger occurred when 1400 patients Complete 12 <12 month FU Complete 24 month follow-up reached 12-month follow-up. month FU • Observed 24-month outcomes Information used to inform modeling Final outcomes modeled  Interim Bayesian Analysis of the 2Year Number of Subjects N=1400 were used to inform modeling. ~35% Primary Endpoint timed to occur when 1400 • Subjects who had not reached subjects have been followed for 12 months 24-month follow-up had their ~50%  Analysis using modeling to include all patient ~15% data outcomes imputed using their last known event status. • Combining imputed and observed data, the posterior distribution of the difference in 2012 2013 2014 2015 2016 24-month event rates was calculated. Attempted Procedure Date 27

  28. Baseline Cardiac Risk Factors* n (%) TAVR (N=864) SAVR (N=796) Coronary artery disease 541 (62.6) 511 (64.2) Prior CABG 138 (16.0) 137 (17.2) Prior PCI 184 (21.3) 169 (21.2) Prior myocardial infarction 125 (14.5) 111 (13.9) Congestive heart failure 824 (95.4) 769 (96.6) History of arrhythmia 275 (31.8) 250 (31.4) Atrial fibrillation 243 (28.1) 211 (26.5) NYHA Class III/IV 520 (60.2) 463 (58.2) *mITT population; no significant difference in any baseline characteristics 28

  29. Baseline Frailty, Disabilities and Comorbidities* n (%) or mean ± SD TAVR (N=864) SAVR (N=796) Body mass index <21 kg/m 2 20 (2.3) 21 (2.6) Falls in past 6 months 102 (11.8) 101 (12.7) 5 meter gait speed >6 s 428 (51.8) 403 (52.9) 254.1 ± 115.8 260.9 ± 117.9 6 minute walk test (meters) Grip strength below threshold 519 (62.5) 490 (63.1) Does not live independently 18 (2.1) 22 (2.8) Chronic lung disease (mod/severe) 115 (13.3) 106 (13.3) Home oxygen 18 (2.1) 21 (2.6) Cirrhosis of the liver 4 (0.5) 5 (0.6) Immunosuppressive therapy 64 (7.4) 68 (8.5) *mITT population; no significant difference in any baseline characteristics 29

More recommend